Go online to PeerView.com/TRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to bring the new standard of care for advanced renal cell carcinoma (RCC) into your clinical practice? Join PeerView and KCCure to learn what the latest research on multi-targeted TKIs, immune checkpoint inhibitors, and combination strategies (dual checkpoint blockade and immune checkpoint inhibitor/TKI combinations) means for your patients with advanced disease. Our panel of experts will discuss how highly efficacious therapeutic strategies are changing outcomes in earlier lines of treatment and the potential for approved agents to be used in new settings. With illustrative patient cases guiding the discussion, this engaging activity will provide participants with the information they need to navigate important clinical decisions, including how to sequence available therapies; which systemic therapies to use in patients with metastatic, locally advanced, or high-risk localized disease; what steps should be taken to manage AEs associated with newer treatment strategies; and which patients could benefit from clinical trial enrollment. Don’t miss this opportunity to learn more about providing guideline-recommended individualized care for your patients with RCC. Upon completion of this CE activity, participants will be able to: Incorporate novel therapeutic approaches, latest clinical evidence, expert recommendations, and patient-, disease-, and treatment-specific factors in the development of contemporary, personalized management plans for patients with RCC, Recommend clinical trials evaluating novel agents and/or combination approaches as standard treatment options for eligible patients with RCC across the disease spectrum, Apply evidence-based strategies and best practices to diagnose, mitigate, and manage AEs related to novel systemic therapies, including combination regimens, for patients with RCC.
View all episodes
